ADC Therapeutics (NYSE:ADCT) Shares Gap Up After Earnings Beat

ADC Therapeutics SA (NYSE:ADCT)’s share price gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $4.23, but opened at $4.54. ADC Therapeutics shares last traded at $4.4050, with a volume of 121,450 shares changing hands.

The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.23.

Key Headlines Impacting ADC Therapeutics

Here are the key news stories impacting ADC Therapeutics this week:

• Positive Sentiment: Q4 and FY results topped expectations: ADC reported better‑than‑expected EPS (loss narrower than consensus) and product revenues, with Q4 net product revenue of ~$22.3M and full‑year product revenue of ~$73.6M — evidence of commercial traction for ZYNLONTA. PR Newswire: Financial Results
• Positive Sentiment: Profitability metrics beat estimates: reported EPS was materially better than Street forecasts (beats of ~$0.23 on one consensus), which traders typically reward. Zacks: Q4 Results
• Positive Sentiment: Commercial and clinical catalysts reaffirmed: management outlined a $600M–$1B peak revenue target for ZYNLONTA and reiterated progress on LOTIS‑5 and LOTIS‑7 (LOTIS‑5 Phase 3 topline due Q2 2026; full data for both by year‑end 2026) — upcoming readouts are major potential upside events. Seeking Alpha: Commercial/Clinical Outlook
• Neutral Sentiment: Balance sheet and financing: cash and equivalents of ~$261.3M support operations with an expected runway into at least 2028; a recent amendment to a HealthCare Royalty financing deal was announced to increase strategic flexibility — lowers near‑term financing risk but details determine net impact. PR Newswire: Cash & Financing
• Negative Sentiment: Company remains unprofitable and analysts still expect negative EPS for the year; revenue base is growing but loss profile and dependency on clinical readouts keep risk high. Earnings Call Transcript

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of ADC Therapeutics in a research report on Wednesday, January 21st. Guggenheim reissued a “buy” rating and set a $10.00 price objective on shares of ADC Therapeutics in a research report on Wednesday, November 12th. Royal Bank Of Canada restated an “outperform” rating and set a $5.00 target price on shares of ADC Therapeutics in a report on Wednesday, December 3rd. Finally, Wall Street Zen raised shares of ADC Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, ADC Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $7.33.

Institutional Trading of ADC Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ADCT. Eventide Asset Management LLC purchased a new position in ADC Therapeutics during the fourth quarter valued at $11,875,000. Nantahala Capital Management LLC grew its stake in shares of ADC Therapeutics by 141.6% in the fourth quarter. Nantahala Capital Management LLC now owns 5,475,433 shares of the company’s stock worth $19,328,000 after acquiring an additional 3,209,144 shares during the last quarter. TCG Crossover Management LLC purchased a new stake in shares of ADC Therapeutics in the third quarter worth $5,561,000. Lynx1 Capital Management LP bought a new position in shares of ADC Therapeutics during the third quarter valued at $5,303,000. Finally, Prosight Management LP increased its holdings in shares of ADC Therapeutics by 13.5% during the fourth quarter. Prosight Management LP now owns 8,477,338 shares of the company’s stock valued at $29,925,000 after acquiring an additional 1,005,035 shares in the last quarter. Hedge funds and other institutional investors own 41.10% of the company’s stock.

ADC Therapeutics Stock Performance

The stock has a market cap of $594.00 million, a PE ratio of -3.31 and a beta of 1.92. The firm has a 50-day moving average price of $3.89 and a 200-day moving average price of $3.87.

About ADC Therapeutics

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.